Autolus Limited

This study tests a one-time treatment called Obe-cel, made from a patient's own immune cells, for severe lupus nephritis that hasn't improved with standard care. About 35 people aged 12 to 65 will receive the infusion and be monitored for up to 24 months. The main goal is to see …

This early-stage trial is testing a new treatment called obe-cel, a type of cell therapy (CAR T-cell), for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. The main goal is to see if it's safe, but researchers will also look for any s…

This early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are…

This early-phase trial is testing a one-time treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't improved with standard treatments. Obe-cel is made by taking a patient's own immune cells, engineering them to target and attack faulty B cells…

This expanded access program provides an experimental CAR-T cell therapy called obe-cel to adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) who have no other treatment options. The therapy is made from the patient's own blood cells but did not meet com…